Nevertheless, biochemical recurrence (BCR), defined by increased serum PSA levels following prostatectomy or radiation therapy for clinically localized PCa, has been shown to predict metastatic progression (MP) and prostate cancer-specific mortality (PCSM) by a median of 8 years and 13 years, respectively [16, 17]. This evidence concerns the gene KLK3 and posterior cortical atrophy.